Soligenix Inc. (NASDAQ:SNGX) Sees Large Decrease in Short Interest

Soligenix Inc. (NASDAQ:SNGX – Get Free Report) was the target of a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 479,055 shares, a drop of 92.6% from the May 31st total of 6,514,042 shares. Currently, 3.3% of the company’s shares are sold short. Based on an average trading volume of 3,609,843 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Soligenix in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $6.00.

Get Soligenix alerts:

Read Our Latest Stock Analysis on Soligenix

Soligenix Stock Up 1.0%

Soligenix stock traded up $0.00 during mid-day trading on Thursday, hitting $0.40. 910,919 shares of the company’s stock were exchanged, compared to its average volume of 3,998,306. The company’s 50 day simple moving average is $0.62 and its 200-day simple moving average is $1.04. The firm has a market capitalization of $5.85 million, a P/E ratio of -0.24 and a beta of 1.84. Soligenix has a fifty-two week low of $0.28 and a fifty-two week high of $6.23.

Soligenix (NASDAQ:SNGX – Get Free Report) last posted its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. Research analysts expect that Soligenix will post -0.9 EPS for the current year.

Institutional Trading of Soligenix

A number of large investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in Soligenix during the 4th quarter worth approximately $37,000. Jane Street Group LLC bought a new position in Soligenix in the fourth quarter valued at approximately $51,000. StoneX Group Inc. acquired a new position in shares of Soligenix in the fourth quarter valued at approximately $50,000. Geode Capital Management LLC increased its position in shares of Soligenix by 88.8% during the fourth quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 37,811 shares in the last quarter. Finally, Armistice Capital LLC bought a new stake in shares of Soligenix during the third quarter worth $821,000. 3.60% of the stock is owned by institutional investors.

About Soligenix

(Get Free Report)

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.

Featured Articles

• Five stocks we like better than Soligenix
• MDA Space Targets US Defense Market With $620M Acquisition
• Carnival’s Second Quarter: Is the Stock Still Complicated?
• Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
• Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.